WebPathol Oncol Res. 2012;18(2):331–342. 25. Adam MA. New prognostic factors in breast cancer. Adv Clin Exp Med. 2013;22(1):5–15. 26. Ivanova L, Zandberga E, Silina K, et al. Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast ... Web2. Ogitani Y, et al. Clin Cancer Res. 2016;22:5097-108. 3. Modi S, et al. J Clin Oncol 2024;38:1887-96. T-DXd MOA, Bystander Effect, and Rationale for Targeting HER2-low …
Nivolumab in Resected and Unresectable Metastatic Melanoma ...
WebJan 1, 2024 · Clin Cancer Res 2016; 22:5097–108. [Google Scholar] 29. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer ... WebApr 1, 2024 · HER2 is overexpressed in approximately 20% of esophagogastric cancer (EGC) cases. The addition of the anti-HER2 antibody, trastuzumab, to chemotherapy in 2010 was the first targeted treatment to demonstrate an improvement in survival. The aggressive nature and heterogeneous biology of EGC have posed a particular challenge … au u03 認識しない
Trastuzumab Emtansine (T-DM1) in Patients with Previously …
WebAug 14, 2016 · Clin Cancer Res; 22(16); 3992–8. ©2016 AACR. Disclosure of Potential Conflicts of Interest M.S. Carlino is a consultant/advisory board member for Bristol-Myers Squibb, GlaxoSmithKline/Novartis, and Merck/MSD. G.V. Long is a consultant/advisory board member for Amgen, Bristol-Myers Squibb, GlaxoSmithKline/Novartis, Merck/MSD, … WebDec 31, 2024 · Clin Cancer Res. 2016;22:5097–108. Article CAS Google Scholar Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. WebСклад кон'югата антитіла з лікарським засобом. Кон'югат антитіла з лікарським засобом складається з 3 компонентів: антитіла, яке націлено на мішень препарату, і може також спричинювати лікувальну дію. au u15 ピタットプラン 4g lte